SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : EBIO: Epoch Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (2)12/28/2000 2:40:50 PM
From: JR  Read Replies (1) | Respond to of 33
 
Tuck-Thanks for your response. Can you post specifics of Auerbach's revised #'s. Epoch's management stated that the acquisition would accelerate the rate of revenue growth (increased 2001 revs. significantly). Also said that they were staying with the projection of breakeven for 2002.
Like to see what Auerbach came away with.

Thanks



To: tuck who wrote (2)12/28/2000 3:05:27 PM
From: Biomaven  Read Replies (1) | Respond to of 33
 
tuck,

EBIO went in my year-end tax-loss selling (not much of a loss for me, but I was ruthless).

Maybe the overall tax-loss selling is what's driving it at the moment. (If so, it might bounce in January).

Can't believe either the increased loss forecast or the pressure on the price is due to the small acquisition.

Peter



To: tuck who wrote (2)1/2/2001 2:32:24 PM
From: JR  Read Replies (1) | Respond to of 33
 
Tuck-still interested in Auerbach's estimate of EBIO's 2001 losses, which you said he increased "dramatically". In his earlier report, he had a 9 cents loss per share on $3.8 million in revenues. EBIO has increased the revenue estimate to $11 million for 2001. So, where did he take the earnings loss to and based on what?

Thanks


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News